Literature DB >> 26697473

Combined BRAF and MEK inhibition in BRAF(V600E) mutant melanoma: a synergistic and potentially safe combination partner with immunotherapy.

Patrick A Ott1.   

Abstract

Entities:  

Year:  2015        PMID： 26697473      PMCID： PMC4669316          DOI： 10.3978/j.issn.2305-5839.2015.10.17

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Improved overall survival in melanoma with combined dabrafenib and trametinib.

Authors:  Caroline Robert; Boguslawa Karaszewska; Jacob Schachter; Piotr Rutkowski; Andrzej Mackiewicz; Daniil Stroiakovski; Michael Lichinitser; Reinhard Dummer; Florent Grange; Laurent Mortier; Vanna Chiarion-Sileni; Kamil Drucis; Ivana Krajsova; Axel Hauschild; Paul Lorigan; Pascal Wolter; Georgina V Long; Keith Flaherty; Paul Nathan; Antoni Ribas; Anne-Marie Martin; Peng Sun; Wendy Crist; Jeff Legos; Stephen D Rubin; Shonda M Little; Dirk Schadendorf
Journal:  N Engl J Med       Date:  2014-11-16       Impact factor: 91.245

2.  Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.

Authors:  Georgina V Long; Daniil Stroyakovskiy; Helen Gogas; Evgeny Levchenko; Filippo de Braud; James Larkin; Claus Garbe; Thomas Jouary; Axel Hauschild; Jean Jacques Grob; Vanna Chiarion Sileni; Celeste Lebbe; Mario Mandalà; Michael Millward; Ana Arance; Igor Bondarenko; John B A G Haanen; Johan Hansson; Jochen Utikal; Virginia Ferraresi; Nadezhda Kovalenko; Peter Mohr; Volodymyr Probachai; Dirk Schadendorf; Paul Nathan; Caroline Robert; Antoni Ribas; Douglas J DeMarini; Jhangir G Irani; Michelle Casey; Daniele Ouellet; Anne-Marie Martin; Ngocdiep Le; Kiran Patel; Keith Flaherty
Journal:  N Engl J Med       Date:  2014-09-29       Impact factor: 91.245

3.  Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.

Authors:  Michael A Postow; Jason Chesney; Anna C Pavlick; Caroline Robert; Kenneth Grossmann; David McDermott; Gerald P Linette; Nicolas Meyer; Jeffrey K Giguere; Sanjiv S Agarwala; Montaser Shaheen; Marc S Ernstoff; David Minor; April K Salama; Matthew Taylor; Patrick A Ott; Linda M Rollin; Christine Horak; Paul Gagnier; Jedd D Wolchok; F Stephen Hodi
Journal:  N Engl J Med       Date:  2015-04-20       Impact factor: 91.245

4.  Selective BRAFV600E inhibition enhances T-cell recognition of melanoma without affecting lymphocyte function.

Authors:  Andrea Boni; Alexandria P Cogdill; Ping Dang; Durga Udayakumar; Ching-Ni Jenny Njauw; Callum M Sloss; Cristina R Ferrone; Keith T Flaherty; Donald P Lawrence; David E Fisher; Hensin Tsao; Jennifer A Wargo
Journal:  Cancer Res       Date:  2010-06-15       Impact factor: 12.701

5.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Authors:  Suzanne L Topalian; F Stephen Hodi; Julie R Brahmer; Scott N Gettinger; David C Smith; David F McDermott; John D Powderly; Richard D Carvajal; Jeffrey A Sosman; Michael B Atkins; Philip D Leming; David R Spigel; Scott J Antonia; Leora Horn; Charles G Drake; Drew M Pardoll; Lieping Chen; William H Sharfman; Robert A Anders; Janis M Taube; Tracee L McMiller; Haiying Xu; Alan J Korman; Maria Jure-Kunkel; Shruti Agrawal; Daniel McDonald; Georgia D Kollia; Ashok Gupta; Jon M Wigginton; Mario Sznol
Journal:  N Engl J Med       Date:  2012-06-02       Impact factor: 91.245

6.  BRAF inhibitor vemurafenib improves the antitumor activity of adoptive cell immunotherapy.

Authors:  Richard C Koya; Stephen Mok; Nicholas Otte; Kevin J Blacketor; Begonya Comin-Anduix; Paul C Tumeh; Aspram Minasyan; Nicholas A Graham; Thomas G Graeber; Thinle Chodon; Antoni Ribas
Journal:  Cancer Res       Date:  2012-06-12       Impact factor: 12.701

7.  The activation of MAPK in melanoma cells resistant to BRAF inhibition promotes PD-L1 expression that is reversible by MEK and PI3K inhibition.

Authors:  Xiaofeng Jiang; Jun Zhou; Anita Giobbie-Hurder; Jennifer Wargo; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2012-10-24       Impact factor: 12.531

8.  BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

Authors:  Dennie T Frederick; Adriano Piris; Alexandria P Cogdill; Zachary A Cooper; Cecilia Lezcano; Cristina R Ferrone; Devarati Mitra; Andrea Boni; Lindsay P Newton; Chengwen Liu; Weiyi Peng; Ryan J Sullivan; Donald P Lawrence; F Stephen Hodi; Willem W Overwijk; Gregory Lizée; George F Murphy; Patrick Hwu; Keith T Flaherty; David E Fisher; Jennifer A Wargo
Journal:  Clin Cancer Res       Date:  2013-01-10       Impact factor: 12.531

9.  The BRAF-MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells.

Authors:  Hidetoshi Sumimoto; Fumie Imabayashi; Tomoko Iwata; Yutaka Kawakami
Journal:  J Exp Med       Date:  2006-06-26       Impact factor: 14.307

Review 10.  Impact of MAPK Pathway Activation in BRAF(V600) Melanoma on T Cell and Dendritic Cell Function.

Authors:  Patrick A Ott; Nina Bhardwaj
Journal:  Front Immunol       Date:  2013-10-28       Impact factor: 7.561
View more
  2 in total

1.  Dabrafenib and Trametinib prolong coagulation through the inhibition of tissue factor in BRAFv600e mutated melanoma cells in vitro.

Authors:  Cristian Scatena; Sara Franceschi; Chiara Maria Mazzanti; Antonio Giuseppe Naccarato; Maria Franzini; Chiara Sanguinetti; Nadia Romiti; Laura Caponi; Mario Mandalà
Journal:  Cancer Cell Int       Date:  2019-08-28       Impact factor: 5.722

2.  Combination therapy for melanoma with BRAF/MEK inhibitor and immune checkpoint inhibitor: a mathematical model.

Authors:  Xiulan Lai; Avner Friedman
Journal:  BMC Syst Biol       Date:  2017-07-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.